LifeTech Capital Maintains Echo Therapeutics Strong Speculative Buy, $6 PT

LifeTech Capital maintained its Echo Therapeutics

Strong Speculative Buy and $6 price target in a research report published today. In the report, LifeTech Capital states, "Echo Therapeutics Symphony™ transdermal continuous glucose monitor (tCGM) system is a unique needle-free, wireless system which we believe is set to begin a pivotal clinical trial in ICU/Critical Care patients H1 2012 (following a final pilot trial). We believe this puts Echo Therapeutics ahead of the curve with respect to tougher FDA standards for hospital use. (see FDA to Require Hospitals to Use More Accurate Glucose Monitors)." Shares of Echo Therapeutics were trading at $3.10 at the time of posting, down 3.13% from Wednesday's market close.